SKB264 Plus Inetetamab
Phase 2Monoclonal antibody
SKB264 Plus Inetetamab is one of 9 small molecule programs targeting Locally Advanced or Metastatic Breast Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Locally Advanced or Metastatic Breast Cancer
#DrugCompanyPhaseTrials
1Truqap
AstraZenecaPhase 3
Afinitor
NovartisPhase 3
Faslodex
FFresenius Kabi USA, LLC
Phase 3
PHESGO
RochePhase 3
Giredestrant
RochePhase 3
LHRH Agonist
RochePhase 3
SIM0270
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
SKB264 Plus Inetetamab
FFudan University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SKB264 Plus Inetetamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University